Premenstrual Syndrome - Pipeline Review, Q2 2011
Summary
Global Markets Direct’s, 'Premenstrual Syndrome - Pipeline Review, Q2 2011', provides an overview of the Premenstrual Syndrome therapeutic pipeline. This report provides information on the therapeutic development for Premenstrual Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Premenstrual Syndrome. 'Premenstrual Syndrome - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
Summary
Global Markets Direct’s, 'Premenstrual Syndrome - Pipeline Review, Q2 2011', provides an overview of the Premenstrual Syndrome therapeutic pipeline. This report provides information on the therapeutic development for Premenstrual Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Premenstrual Syndrome. 'Premenstrual Syndrome - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Premenstrual Syndrome.
- A review of the Premenstrual Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Premenstrual Syndrome pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
- Identify and understand important and diverse types of therapeutics under development for Premenstrual Syndrome.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Premenstrual Syndrome pipeline depth and focus of Premenstrual Syndrome therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Premenstrual Syndrome Overview
Therapeutics Development
An Overview of Pipeline Products for Premenstrual Syndrome
Premenstrual Syndrome Therapeutics under Development by Companies
Premenstrual Syndrome Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Premenstrual Syndrome Therapeutics - Products under Development by Companies
Premenstrual Syndrome Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Premenstrual Syndrome Therapeutics Development
M et P Pharma AG
Umecrine Mood AB
Pherin Pharmaceuticals, Inc.
DEKK-TEC, Inc.
Premenstrual Syndrome - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ProgestoMat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CDB-2914 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PH80-PMD - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dutasteride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
UC1010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Progestrone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Premenstrual Syndrome - Featured News
Jul 29, 2010: Bayer increases sales and earnings in the second quarter
Sep 08, 2008: New low-dose oral contraceptive YAZ launched in Europe
Jun 24, 2008: Bayer concludes supply and licensing agreements for Yasmin and YAZ with Barr for the United States
May 06, 2008: Bayer Schering Pharma to market new low-dose oral contraceptive YAZ in Europe
Mar 03, 2008: Court decides against Bayer’s Yasmin patent
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products Under Development for Premenstrual Syndrome, Q2 2011
Products under Development for Premenstrual Syndrome – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Early Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
M et P Pharma AG, 2011
Umecrine Mood AB, 2011
Pherin Pharmaceuticals, Inc., 2011
DEKK-TEC, Inc., 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
LIST OF FIGURES
Number of Products under Development for Premenstrual Syndrome, Q2 2011
Products under Development for Premenstrual Syndrome – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Early Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Premenstrual Syndrome Overview
Therapeutics Development
An Overview of Pipeline Products for Premenstrual Syndrome
Premenstrual Syndrome Therapeutics under Development by Companies
Premenstrual Syndrome Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Premenstrual Syndrome Therapeutics - Products under Development by Companies
Premenstrual Syndrome Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Premenstrual Syndrome Therapeutics Development
M et P Pharma AG
Umecrine Mood AB
Pherin Pharmaceuticals, Inc.
DEKK-TEC, Inc.
Premenstrual Syndrome - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ProgestoMat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CDB-2914 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PH80-PMD - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dutasteride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
UC1010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Progestrone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Premenstrual Syndrome - Featured News
Jul 29, 2010: Bayer increases sales and earnings in the second quarter
Sep 08, 2008: New low-dose oral contraceptive YAZ launched in Europe
Jun 24, 2008: Bayer concludes supply and licensing agreements for Yasmin and YAZ with Barr for the United States
May 06, 2008: Bayer Schering Pharma to market new low-dose oral contraceptive YAZ in Europe
Mar 03, 2008: Court decides against Bayer’s Yasmin patent
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products Under Development for Premenstrual Syndrome, Q2 2011
Products under Development for Premenstrual Syndrome – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Early Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
M et P Pharma AG, 2011
Umecrine Mood AB, 2011
Pherin Pharmaceuticals, Inc., 2011
DEKK-TEC, Inc., 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
LIST OF FIGURES
Number of Products under Development for Premenstrual Syndrome, Q2 2011
Products under Development for Premenstrual Syndrome – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Early Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011
